Peter A. Sears
Directeur/Membre du Conseil chez Protez Pharmaceuticals, Inc.
Profil
Mr. Peter A.
Sears is on the Board of Directors at Protez Pharmaceuticals, Inc. and Vybion, Inc.
Mr. Sears was previously employed as Chairman by SMART Biosciences, Inc., General Counsel by GlaxoSmithKline Plc, Independent Director by Fox Chase Bancorp, Inc., and President & Vice President-Business Investments by SR One Ltd.
He also served on the board at AVANT Immunotherapeutics, Inc., Fox Chase Bank, and Immune Control, Inc.
He received his undergraduate degree from Colgate University and a graduate degree from Harvard University.
Postes actifs de Peter A. Sears
| Sociétés | Poste | Début |
|---|---|---|
Protez Pharmaceuticals, Inc.
 Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Peter A. Sears
| Sociétés | Poste | Fin |
|---|---|---|
Immune Control, Inc.
 Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Directeur/Membre du Conseil | 06/12/2012 |
| FOX CHASE BANCORP, INC. | Directeur/Membre du Conseil | 25/06/2009 |
Fox Chase Bank
 Fox Chase Bank Real Estate DevelopmentFinance Fox Chase Bank operates residential houses. The company is based in Hatboro, PA. | Directeur/Membre du Conseil | 24/05/2012 |
SMART Biosciences, Inc.
 SMART Biosciences, Inc. BiotechnologyHealth Technology At SMART Biosciences they are engaged in a coordinated effort to discover and develop novel small-molecule therapeutics to treat major age-related illnesses, including Alzheimer's disease and various forms of cancer. Since its beginning in 2005, as a spin-off of Columbia University, they have been working to address significant unmet therapeutic needs in these large and rapidly growing markets. Through its affiliation with Columbia University, SMART holds exclusive worldwide licenses to valuable intellectual property. Its scientists have identified several novel targets in two therapeutic areas that have the potential for new treatments in: Alzheimer's disease--a novel lipid target that modulates levels of neurotoxic beta-amyloid in the brain, Cancer--novel targets that modulate p53 stability, increasing tumor-cell sensitivity to cytotoxic and radiation therapies. They believe its intellectual property and scientific rationale for future compound discovery offers a compelling opportunity for commercialization. SMART is led by management and scientific advisory teams comprised of preeminent professionals distinguished in the worlds of academic science, pharmaceutical discovery, business/corporate development, finance and intellectual property law. The SMART Biosciences leadership team brings scientific rigor, business leadership, and innovation experience to its endeavors. Its discovery and development strategy employs a unique-to-the-industry collaborative network of advanced business, academic and R&D interests throughout the United States and Asia. | Président | 13/02/2012 |
AVANT Immunotherapeutics, Inc.
 AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Directeur/Membre du Conseil | 26/11/2007 |
Formation de Peter A. Sears
| Harvard University | Graduate Degree |
| Colgate University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 8 |
|---|---|
AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Fox Chase Bancorp, Inc.
 Fox Chase Bancorp, Inc. Regional BanksFinance Fox Chase Bancorp, Inc. is the holding company of Fox Chase Bank, which is a federally chartered savings bank. Its business activities consist of the ownership of the bank's capital stock, making loans to the employee stock ownership plan and the management of the offering proceeds it retained. The company was founded on September 29, 2006 and is headquartered in Hatboro, PA. | Finance |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
Protez Pharmaceuticals, Inc.
Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Health Technology |
Immune Control, Inc.
Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Health Technology |
Fox Chase Bank
Fox Chase Bank Real Estate DevelopmentFinance Fox Chase Bank operates residential houses. The company is based in Hatboro, PA. | Finance |
SMART Biosciences, Inc.
SMART Biosciences, Inc. BiotechnologyHealth Technology At SMART Biosciences they are engaged in a coordinated effort to discover and develop novel small-molecule therapeutics to treat major age-related illnesses, including Alzheimer's disease and various forms of cancer. Since its beginning in 2005, as a spin-off of Columbia University, they have been working to address significant unmet therapeutic needs in these large and rapidly growing markets. Through its affiliation with Columbia University, SMART holds exclusive worldwide licenses to valuable intellectual property. Its scientists have identified several novel targets in two therapeutic areas that have the potential for new treatments in: Alzheimer's disease--a novel lipid target that modulates levels of neurotoxic beta-amyloid in the brain, Cancer--novel targets that modulate p53 stability, increasing tumor-cell sensitivity to cytotoxic and radiation therapies. They believe its intellectual property and scientific rationale for future compound discovery offers a compelling opportunity for commercialization. SMART is led by management and scientific advisory teams comprised of preeminent professionals distinguished in the worlds of academic science, pharmaceutical discovery, business/corporate development, finance and intellectual property law. The SMART Biosciences leadership team brings scientific rigor, business leadership, and innovation experience to its endeavors. Its discovery and development strategy employs a unique-to-the-industry collaborative network of advanced business, academic and R&D interests throughout the United States and Asia. | Health Technology |
Vybion, Inc.
 Vybion, Inc. Pharmaceuticals: MajorHealth Technology Vybion, Inc. develops human monoclonal antibody drugs. It offers recombinant proteins, including biotherapeutics, viral antigens, cellular proteins, cytokines, and proteins for diagnostic, therapeutic, and reagent applications. The company was founded by Lee A. Henderson in 1995 and is headquartered in Ithaca, NY. | Health Technology |